All lobbying filings

ARENTFOX SCHIFF LLP

Lobbying for ORGANOGENESIS INC. · Biotech company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $70,000.00 income · posted Jan 20, 2026

Official filing document

Bills named in this filing 4

HR 5768
Skin Substitute Access and Payment Reform Act
S 2561
Skin Substitute Access and Payment Reform Act of 2025
HR 5304
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
S 2587
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026

Lobbying activity 2

Medicare/Medicaid

Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products (CY2026) Hospital Outpatient Prospective Payment System regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 5304 and S. 2587 (Departments of Labor, Health and Human Services, and Education and Related Agencies Appropriations Act, 2026), regarding reimbursement for chronic wound healing products

Health Issues

Food and Drug Administration policy on chronic wound healing products

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.